A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-23. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
The DXP-independent PLP-biosynthetic route consists of a step catalyzed by Pyridoxal 5'-phosphate synthase (glutamine hydrolyzing), an enzyme composed of two subunits. PdxS catalyzes the condensation of ribulose 5-phosphate, glyceraldehyde-3-phosphate, and ammonia, this latter molecules is produced by PdxT which catalyzes the production of ammonia from glutamine. PdxS is a (β/α)8 barrel (also known as a TIM-barrel) that forms a dodecamer.
x = mass of adsorbate m = mass of adsorbent p = equilibrium pressure of the gaseous adsorbate in case of experiments made in the gas phase (gas/solid interaction with gaseous species/adsorbed species) K and n are constants for a given adsorbate and adsorbent at a given temperature (from there, the term isotherm needed to avoid significant gas pressure fluctuations due to uncontrolled temperature variations in the case of adsorption experiments of a gas onto a solid phase).
== Controversy == In 2024, an Oregon man and the ACLU of Oregon filed a lawsuit against Grifols for its alleged "forever ban" on accepting plasma from gay men. The ACLU of Oregon states this alleged ban is discriminatory and a violation of Oregon's public accommodations laws. The plaintiff sought nearly $1 million in damages. In 2025, the U.S. Equal Employment Opportunity Commission (EEOC) sued Grifols for failing to accommodate a job applicant's disability, a violation of the Americans with Disabilities Act. In 2025, a Manitoba man sued Grifols, claiming a machine malfunction during plasmapheresis caused him a serious kidney injury. After the deaths of two individuals who gave plasma at Grifols facilities in Winnipeg, the company halted plasma collection in Canada effective August 2026 but indicated it remains ready to resume.
Describes a clinical trial or other experiment in which the researchers know what treatments are being given to each study subject or experimental group. If human subjects are involved, they know what treatments they are receiving. (NCI) Nonclinical Study
Sources: en.wikipedia.org
Banting House features archival materials, artifacts, and other ephemera associated with Banting as co-discoverer of insulin, doctor, and artist, as well as his involvement in the first and second world wars. One gallery depicts the kind of office Banting might have had, and contains several of his belongings, including his original medicine cabinet, and a graduated cylinder Banting used during his time at the University of Western Ontario. The apothecary in the next room features a sink that Banting installed for his medical practice. Other galleries in the museum hold original belongings of Banting as well, most notably his desk and his bed frame. The bed frame is kept in Banting's bedroom, and visitors are encouraged to take a moment or a picture with it, as it is not roped off like many other areas of the museum. Additionally, an official replica of the Nobel Prize medal co-awarded to Banting and Macleod is on display, as well as many of Banting's other medals. Other displays include the military gallery, which includes a representation of the type of operating room Banting would have worked in on the field during the First World War, some information on the projects he headed during the Second World War, and an entire gallery filled with artwork done by Banting.
== References == Allen, Ira (1969) [1798]. The natural and political history of the State of Vermont, one of the United States of America. Charles E. Tuttle Company. ISBN 0-8048-0419-2. Cooper, Grace Rogers (1973). Thirteen Star Flags (PDF). Smithsonian Institution Press. Archived (PDF) from the original on 2022-10-09. Tuttle, Mrs. George F. (1909). 300 Years In The Champlain Valley. Saranac, NY: Daughters of the American Revolution. Van de Water, Frederic Franklyn (1974). The Reluctant Republic: Vermont 1724–1791. The Countryman Press. ISBN 0-914378-02-3. Shalhope, Robert. (1996). Bennington and the Green Mountain Boys: The Emergence of Liberal Democracy in Vermont, 1760-1850. Johns Hopkins University Press
Subclass Nautiloidea: Fundamental ectocochliate cephalopods that provided the source for the Ammonoidea and Coleoidea. Order † Plectronocerida: the ancestral cephalopods from the Cambrian Period Order † Ellesmerocerida (500 to 470 Ma) Order † Endocerida (485 to 430 Ma) Order † Actinocerida (480 to 312 Ma) Order † Discosorida (482 to 392 Ma) Order † Pseudorthocerida (432 to 272 Ma) Order † Tarphycerida (485 to 386 Ma) Order † Oncocerida (478.5 to 324 Ma) Order Nautilida (extant; 410.5 Ma to present) Order † Orthocerida (482.5 to 211.5 Ma) Order † Ascocerida (478 to 412 Ma) Order † Bactritida (418.1 to 260.5 Ma) Subclass † Ammonoidea: ammonites (479 to 66 Ma) Order † Goniatitida (388.5 to 252 Ma) Order † Ceratitida (254 to 200 Ma) Order † Ammonitida (215 to 66 Ma) Subclass Coleoidea (410.0 Ma-Rec) Cohort † Belemnoidea: Belemnites and kin Genus † Jeletzkya Order † Aulacocerida (265 to 183 Ma) Order † Phragmoteuthida (189.6 to 183 Ma) Order † Hematitida (339.4 to 318.1 Ma) Order † Belemnitida (339.4 to 66 Ma) Genus † Belemnoteuthis (189.6 to 183 Ma) Cohort Neocoleoidea Superorder Decapodiformes (also known as Decabrachia or Decembranchiata) Order Spirulida: ram's horn squid Order Sepiida: cuttlefish Order Sepiolida: pygmy, bobtail and bottletail squid Order Idiosepida Order Oegopsida: neritic squid Order Myopsida: coastal squid Order Bathyteuthida Superorder Octopodiformes (also known as Vampyropoda) Family † Trachyteuthididae Order Vampyromorphida: vampire squid Order Octopoda: octopus Superorder † Palaeoteuthomorpha Order † Boletzkyida Other classifications differ, primarily in how the various decapod orders are related, and whether they should be orders or families.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.